Imaging patients with kidney disease in the era of NSF: Can it be done safely?

Clinical Nephrology

Volumn 75, Issue 4, 2011, Pages 279-285

  Manjunath, V ^a   Perazella, M A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CT scan; Gadolinium; Kidney disease; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

COLLAGEN FIBRIL; CONTRAST MEDIUM; ECHOVIST; FERUMOXYTOL; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM BASED CONTRAST; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ANGIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CHRONIC KIDNEY DISEASE; COLLAGEN SYNTHESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DOPPLER ECHOGRAPHY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; IMAGE QUALITY; IRON DEFICIENCY; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CANCER; LIVER CYST; LIVER HEMANGIOMA; METALLATION; MORBIDITY; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PATIENT SAFETY; PROTEIN POLYMERIZATION; RENOGRAPHY; SPIN LABELING; CHEMICALLY INDUCED DISORDER; DIAGNOSTIC IMAGING; REVIEW; RISK FACTOR;

CONTRAST MEDIA; DIAGNOSTIC IMAGING; GADOLINIUM; HUMANS; KIDNEY DISEASES; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS;

EID: 79960946179     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75279     Document Type: Article

References (34)

1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001; 23: 383-393.
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21: 1104-1108.
3. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging. 2009; 30: 1240-1248.
4. Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J. 1983; 213: 751-758.
5. Stratta P, Canavese C, Quaglia M, Fenoglio R. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Rheumatology 2009; 49: 821-823.
6. Perazella MA. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol. 2009; 3: 649-651.
7. Boyd AC, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007; 56: 27-30.
8. Grant D, Johnsen H, Juelsrud A, Lovhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009; 50: 156-169.
9. High WA, Eng M, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007; 56: 1-2.
10. Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009; 19: 1417-1424.
11. Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, Sieber MA. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009; 44: 226-233.
12. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008; 18: 2164-2173.
13. WhiteGW, GibbyWA, TweedleMF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HPDO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy, Invest Radiol. 2006; 41: 272-278.
14. Aime S, Caravan P. Biodistribution of gadoliniumbased contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009; 30: 1259-1267.
15. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998; 5: 491-502.
16. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial. 2007; 20: 179-185.
17. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009; 4: 461-469.
18. Perazella MA. Radiocontrast-induced nephropathy: an update. Minerva Urol Nefrol. 2009; 61: 215-233.
19. Elmholdt TR, Jorgensen B, Ramsing M, Pedersen M, Olesen AB. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. Nephrol Dial Transplant Plus. 2010; 3: 285-287.
20. Chapman A, Grantham JJ, Guay-Woodford LM, et al. Absence of NSF following gadolinium exposure in ADPKD individuals with stable CKD (Abstract). J Am Soc Nephrol. 2007; 18: 837.
21. Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, et al.Lowrisk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010; 5: 484-489.
22. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007; 245: 168-175.
23. Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens. 2009; 18: 519-525.
24. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008; 43: 141-144.
25. Krumme B. Renal Doppler sonography-update in clinical nephrology. Nephron Clin Pract. 2006; 103: 24-28.
26. Gao J, Shih G, Auh YH, Prince MR, Funderburk J, Ng A, Min R. Pitfalls and sources of error of color duplex sonography in screening for renovascular hypertension. Int J Nephrol Urol. 2010; 2: 212-223.
27. Zhang HL, Sos TA, Winchester PA, Gao J, Prince MR. Renal artery stenosis: imaging options, pitfalls, and concerns. Prog Card Dis: 2009; 52: 209-219.
28. Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? Am J Radiol. 2009; 193: 55-60.
29. Dawson P. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies. J Magn Reson Imaging. 2008; 28: 797-804.
30. Fazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH, Shah ND, Nasir K, Einstein AJ, Nallamothu BK. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009; 361: 849-857.
31. Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR,Edelman RD, Jacobs PM,Watnick SG. Kidney Int. 2009; 75: 465-474.
32. Maki JH,Wilson GJ, Eubank WB, Glickerman DJ, Pipavath S, Hoogeveen RM. Steady-state free precession MRAof the renal arteries: breath-hold and navigator-gated techniques vs. CE-MRA. J Magn Reson Imaging. 2007; 26: 966-973.
33. Wilson GJ, Maki JH. Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. Magn Reson Imaging Clin N Am. 2009; 17: 13-27.
34. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010; 254: 47-66.